Immunotherapy News and Research

Latest Immunotherapy News and Research

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Eli Lilly and Company today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.

22 Oct 2015

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

An international team led by researchers from the Broad Institute of MIT and Harvard, the Harvard T.H. Chan School of Public Health, and Fred Hutchinson Cancer Research Center have used cutting edge genomic methods to uncover key biological insights that help explain the protective effects of the world's most advanced malaria vaccine candidate, RTS,S/AS01 (RTS,S).

22 Oct 2015

NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

NHS Blood and Transplant will start producing stem cells for groundbreaking treatment aimed at combating one of the most serious health problems facing the NHS, diabetic kidney disease.

22 Oct 2015

Study shows how dietary fatty acids affect development and progression of multiple sclerosis

Dietary fatty acids affect the development and progression of autoimmune chronic-inflammatory diseases such as multiple sclerosis. In a collaborative study between the Departments of Neurology at the Ruhr-Universität Bochum (St. Josef-Hospital) and the Friedrich Alexander Universtiy Erlangen, researchers now found that long-chain fatty acids promote the development and propagation of CNS reactive immune cells in the intestinal wall. On the contrary, short-chain fatty acids promote the development and propagation of regulatory cells in the immune system.

22 Oct 2015

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee has reviewed the initial safety data from all three patients in the first cohort and has recommended dose escalation to the second cohort.

20 Oct 2015

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.

19 Oct 2015

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.

19 Oct 2015

New research raises hope for novel cancer immunotherapy

New research by Dana-Farber Cancer Institute scientists raises the prospect of cancer therapy that works by converting a tumor's best friends in the immune system into its gravest enemies.

16 Oct 2015

TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships - its core, high added value businesses

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs).

15 Oct 2015

OncoSec reports net loss of $6.5 million for fourth quarter of fiscal 2015

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the fourth quarter and fiscal year ended July 31, 2015.

15 Oct 2015

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

Eli Lilly and Company and ImaginAb Inc. are pleased to announce a preclinical research collaboration to study potential novel T-cell-based immuno-oncology therapies.

13 Oct 2015

ImmunArray launches SLE-key Rule-Out test for lupus patients

Following a limited three-month trial period in which more than one hundred and fifty patients with lupus-like symptoms were tested for the difficult-to-diagnose disease, a new blood test for lupus is being rolled out nationally.

12 Oct 2015

Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

Patients with metastatic melanoma who undergo surgery to remove lesions that have spread into the abdomen live more than twice as long as those treated with drug therapy alone, according to novel new research by a North Shore-LIJ Health System cancer surgeon.

12 Oct 2015

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.

7 Oct 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

Study shows how dietary fatty acids affect development and progression of multiple sclerosis

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

New research raises hope for novel cancer immunotherapy

TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships - its core, high added value businesses

OncoSec reports net loss of $6.5 million for fourth quarter of fiscal 2015

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

ImmunArray launches SLE-key Rule-Out test for lupus patients

Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

FDA awards research grants to boost product development for patients with rare diseases

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in